EPISODE · May 4, 2026 · 2 MIN
Selinexor's Myelofibrosis Data Shines, Upside Potential
from The Daily News Now! Business
Karyopharms Q1 2025 earnings highlight selinexors potential in myelofibrosis, with promising Phase 2 trial results showing improved spleen volume reduction, symptom relief, and better blood counts. The company aims to enroll SENTRY trial by June/July, with data expected by year-end/early 2026. Peak US sales potential in MF could reach $1 billion. Despite lower-than-expected revenue guidance, Karyopharm remains focused on its Phase 3 trials and potential blockbuster opportunities. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/9d80325db705dc3b
NOW PLAYING
Selinexor's Myelofibrosis Data Shines, Upside Potential
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m